Our study identified a novel heterozygous mutation of SLC3A1 for cystinuria based on WES screening of a 5-year-old case and indicated that a gene-mutation-based screening strategy should be considered in the clinic to provide a promising approach for cystine stone diagnosis and clinical management. This evidence concerns the gene SLC3A1 and cystinuria.